Monopar Therapeutics Inc. (MNPR)

NASDAQ: MNPR · IEX Real-Time Price · USD
2.78
+0.09 (3.35%)
Mar 21, 2023, 2:25 PM EDT - Market open
3.35%
Market Cap 34.56M
Revenue (ttm) n/a
Net Income (ttm) -10.30M
Shares Out 12.92M
EPS (ttm) -0.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,350
Open 2.56
Previous Close 2.69
Day's Range 2.56 - 2.82
52-Week Range 1.39 - 4.88
Beta 1.11
Analysts Buy
Price Target 18.02 (+548.2%)
Earnings Date Mar 23, 2023

About MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 19, 2019
Employees 9
Stock Exchange NASDAQ
Ticker Symbol MNPR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for MNPR stock is "Buy." The 12-month stock price forecast is $18.02, which is an increase of 548.20% from the latest price.

Price Target
$18.02
(548.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Monopar to Present at the 35th Annual Roth Conference

WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten...

2 weeks ago - GlobeNewsWire

Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials

WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an...

3 weeks ago - GlobeNewsWire

Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin

WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 month ago - GlobeNewsWire

Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT

WILMETTE, Ill., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 month ago - GlobeNewsWire

Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2

WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

2 months ago - GlobeNewsWire

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend ...

3 months ago - GlobeNewsWire

Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.

4 months ago - Zacks Investment Research

Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Monopar Therapeutics Inc. (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revision...

4 months ago - Zacks Investment Research

Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial

WILMETTE, Ill., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

4 months ago - GlobeNewsWire

Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments

Validive ® Phase 2b/3 Interim Analysis on Track for Q1 2023 Camsirubicin Clinical Data at CTOS 2022 Next Week MNPR-202 Preclinical Data at ASH 2022 in December

4 months ago - GlobeNewsWire

Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202

WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

5 months ago - GlobeNewsWire

Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting

WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

5 months ago - GlobeNewsWire

Monopar's stock gains 13% after completing enrollment for an experimental therapy for cancer patients

Shares of Monopar Therapeutics Inc. MNPR, +6.92% gained 13.5% in premarket trading on Wednesday after the company said it completed enrollment in a Phase 2b clinical trial evaluating its experimental ...

5 months ago - Market Watch

Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis

Interim Analysis Planned for Q1 2023 Interim Analysis Planned for Q1 2023

5 months ago - GlobeNewsWire

Monopar to Present at Roth Inaugural Healthcare Opportunities Conference

WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten...

6 months ago - GlobeNewsWire

Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earning...

7 months ago - Zacks Investment Research

Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments

Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated in Q1 2023 Camsirubicin Phase 1b Dose­-Escalation Trial Now Do...

7 months ago - GlobeNewsWire

Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments

Validive ® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward Interim Camsirubicin Phase 1b Dose-Escalation Trial Clears 3 rd Dose Level, Now Enrolling 4 th

11 months ago - GlobeNewsWire

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments

Validive ® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe

1 year ago - GlobeNewsWire

Monopar to Present at the 34th Annual Roth Conference and Maxim's 2022 Virtual Growth Conference

WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten...

1 year ago - GlobeNewsWire

Monopar Announces Clinical and Preclinical Program Updates

WILMETTE, Ill., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 year ago - GlobeNewsWire

Monopar to Present at the H.C. Wainwright BioConnect Conference

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 year ago - GlobeNewsWire

Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial

WILMETTE, Ill., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 year ago - GlobeNewsWire

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments

First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S. Validive ® Phase 2b/3 VOICE Trial Cleared to Enroll in Europe and on Track for Reaching Interim in H1 2022

1 year ago - GlobeNewsWire

Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma

WILMETTE, Ill., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 year ago - GlobeNewsWire